Study of the Ability of Clarithromycin to Induce Oxidative Stress

Condition(s) targeted: Oxidative Stress

Intervention: Clarithromycin (Drug)

Phase: Phase 1

Status: Recruiting

Sponsored by: Rigshospitalet, Denmark

Official(s) and/or principal investigator(s):
Henrik E Poulsen, dr. med., Principal Investigator, Affiliation: Head of Department, Department of Clinical Pharmacology, Rigshospitalet

Overall contact:
Morten T Pedersen, stud.pharm., Phone: 45-4117-2634, Email: morten.pedersen@rh.regionh.dk

The purpose of the study is to examine whether Klacid® (Clarithromycin) will induce oxidative stress (stress from oxygen) in healthy subjects. This is done by measuring the content of a particular substance in the urine sample, which is released when the body is exposed to oxidative stress. In addition, there will also be taken blood samples, which is analysed for another substance that is indicative of oxidative stress.

Official title: A Randomized, Single Blinded, Open-Label Crossover-Study of the Possible Induction of Oxidative Stress by Clarithromycin in Healthy Subjects

Study design: Screening, Randomized, Open Label, Crossover Assignment, Pharmacodynamics Study

Primary outcome:

Amount of 8-oxo-deoxyguanine in 24 hour-urine measured in nmol/mmol creatinine

Amount of Malondialdehyde in plasma

Secondary outcome:

Amount of Total Vitamin C (Ascorbic acid) in plasma

Caffeine-metabolite ratio in 24 hour-urine

Detailed description: The purpose of the study is to examine whether Klacid® induce oxidative stress in healthy subjects.

Many studies have shown that atherosclerosis can cause acute myocardial infarction (AMI). The development of atherosclerosis is exacerbated by simultaneous infection with Chlamydophila pneumoniae, and its accompanying inflammation. There has been shown a positive association between Chlamydophila pneumoniae antibodies and the incidence of cardiovascular complications, suggesting that Chlamydophila pneumoniae could exacerbate the development of atherosclerosis [1]. It has therefore been tried to treat atherosclerotic AMI- patients prophylactically with macrolide antibiotics (which is used to treat Chlamydia infections), to halt development of the atherosclerosis and the accompanying risk of a new acute myocardial infarction.

Two minor studies have demonstrated a positive effect of macrolide-treatment, why a major Danish study of Clarithromycin was implemented [2-4]. Clarithromycin treatment was tested against placebo in 4373 atherosclerotic patients who had had an AMI. It appeared that the use of clarithromycin led to an increased cardiovascular mortality, which could not be explained [4]. The finding of the study suggests that clarithromycin cannot be used for secondary prophylaxis of cardiovascular complications, but whether clarithromycin can be used for primary prophylaxis is not known.

It has been shown that oxidative stress can participate in the development of cardiovascular complications [5], and it could be such an oxidative stress that had led to the increased mortality in the above study. Especially because a recent american study found evidence that bactericidal antibiotics induce oxidative stress in bacteria, leading to cell death [6]. This oxidative stress contributes significantly to the impact of the bactericidal antibiotics, which was thought to be primarily attributed to their specific drug/target interactions. The same study also examined erythromycin, from which clarithromycin is a derivate. Erythromycin showed no induction of oxidative stress, but clarithromycin is twice as effective as erythromycin, which could be due to oxidative stress caused by clarithromycin.

This study seeks to clarify a possible mechanism for clarithromycin, by an examination on healthy volunteers without atherosclerosis.

Minimum age: 18 Years. Maximum age: 35 Years. Gender(s): Male.

Criteria:

Inclusion Criteria:

- Caucasian

- Non-smoker

- Body mass index (BMI) must be ≥18 and ≤ 30

- Blood pressure must be within the following limits:

- Systolic blood pressure (110 mmHg > X < 140 mmHg)

- Diastolic blood pressure (60 mmHg > Y < 90 mmHg)

- Normal lipid plasma levels:

- Total cholesterol (≤ 6,0 mmol/l)

- HDL-cholesterol (≥ 0,9 mmol/l)

- LDL-cholesterol (≤ 4,5 mmol/l)

- Triglycerides (0,5-2,2 mmol/l)

Exclusion Criteria:

- Smokers

- CRP: > 10 mg/l

- Prolonged QT interval (defined as QTc > 450 msec.)

- Severe renal insufficiency (Cpl (creatinine) > 0100 mmol/l)

- Hereditary galactose intolerance

- A special form of hereditary lactase deficiency (Lapp Lactase deficiency)

- Glucose/galactose malabsorption

- Use of medicines and herbal remedies that affect/is affected by Clarithromycin, or

lead to QT prolongation, for example, cisapride, pimozide, terfenadine, ergotamine, dihydroergotamine, fluconazole, ritonavir, carbamazepine, kinidin, disopyramide, lovastatin, simvastatin, warfarin, acenocoumarol, sildenafil, Tadalafil, vardenafil, theophylline, tolterodine, triazolo benzodiazepins, omeprazole, colchinine, digoxin, zidovudine, phenytoin, valproat, atazanavir, itraconazole, saquinavir

- Inborn condition with prolonged QT interval

- The following disorders:

- Coronary artery disease

- Former cardiac arrhythmias

- Severe heart insufficiency

- Non-compensated hypokalemia (defined as Cpl (K) < 3. 2 mmol/ l) and/or hypomagnesemia

(defined as Cpl (Mg) < 0. 67 mmol/l)

- Bradycardia ( < 50 bpm)

- Known allergy to clarithromycin or other macrolides

- Narcotic

- Eating food supplements

Morten T Pedersen, stud.pharm., Phone: 45-4117-2634, Email: morten.pedersen@rh.regionh.dk

Department of Clinical Pharmacology Q, Rigshospitalet, Blegdamsvej 9, Kopenhagen O 2100, Denmark; Recruiting
Morten T Pedersen, stud.pharm., Phone: 45-4117-2634, Email: morten.pedersen@rh.regionh.dk
Henrik E Poulsen, dr. med., Phone: 45-3545-7671, Email: hepo@rh.regioh.dk
Henrik E Poulsen, dr. med., Principal Investigator
Kasper Brødbæk, cand.med., Sub-Investigator
Morten Petersen, cand.med, Sub-Investigator
Jon T Andersen, cand.med., Sub-Investigator

Related publications:

Muhlestein JB, Anderson JL. Infectious serology and atherosclerosis: how burdensome is the risk? Circulation. 2003 Jan 21;107(2):220-2. No abstract available.

Gupta S, Leatham EW, Carrington D, Mendall MA, Kaski JC, Camm AJ. Elevated Chlamydia pneumoniae antibodies, cardiovascular events, and azithromycin in male survivors of myocardial infarction. Circulation. 1997 Jul 15;96(2):404-7.

Gurfinkel E, Bozovich G, Daroca A, Beck E, Mautner B. Randomised trial of roxithromycin in non-Q-wave coronary syndromes: ROXIS Pilot Study. ROXIS Study Group. Lancet. 1997 Aug 9;350(9075):404-7.

Jespersen CM, Als-Nielsen B, Damgaard M, Hansen JF, Hansen S, Helo OH, Hildebrandt P, Hilden J, Jensen GB, Kastrup J, Kolmos HJ, Kjoller E, Lind I, Nielsen H, Petersen L, Gluud C; CLARICOR Trial Group. Randomised placebo controlled multicentre trial to assess short term clarithromycin for patients with stable coronary heart disease: CLARICOR trial. BMJ. 2006 Jan 7;332(7532):22-7. Epub 2005 Dec 8. Erratum in: BMJ. 2006 Jan 21;332(7534):151.

Dhalla NS, Temsah RM, Netticadan T. Role of oxidative stress in cardiovascular diseases. J Hypertens. 2000 Jun;18(6):655-73. Review.

Kohanski MA, Dwyer DJ, Hayete B, Lawrence CA, Collins JJ. A common mechanism of cellular death induced by bactericidal antibiotics. Cell. 2007 Sep 7;130(5):797-810.

Starting date: May 2008
Ending date: July 2008
Last updated: June 27, 2008